Rationale: There are no studies on withdrawal of inhaled corticosteroids in patients on long-term triple therapy in the absence of frequent exacerbations.
Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation for which recommended treatments include long-acting bronchodilators (long-acting b 2 agonists [LABA] and long-acting muscarinic antagonists [LAMA] ) alone or in combination (LABA/LAMA) (1). The current Global Initiative for Chronic Obstructive Lung Disease strategy document suggests that the addition of inhaled corticosteroids (ICS) to LABA and LAMA in the form of "triple therapy" (LABA plus LAMA plus ICS) is to be reserved for high-risk patients still experiencing exacerbations on LABA/ LAMA therapy (1) . However, most patients with COPD are not frequent exacerbators (2, 3) , and despite current recommendations, many of these patients receive triple therapy (4) . In part, this reflects the historic introduction of ICS plus LABA then LAMA therapy in COPD, and previous guideline recommendations (5, 6 ). This approach is not without risk; the long-term use of ICS is associated with an increased risk of adverse events, including pneumonia (7), mycobacterial infections (8) , diabetes onset and progression (9) , or fractures (10) .
It is therefore important to personalize COPD management by identifying patients who may be more likely to benefit from continued long-term triple therapy and those who would be optimally managed by LABA/LAMA after ICS withdrawal. The WISDOM (Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management) trial showed that in patients with severe to very severe COPD susceptible to exacerbations, the risk of moderate or severe exacerbations was similar in patients who followed a stepwise ICS withdrawal compared with those who continued with ICS (11) . However, there are no data on direct ICS withdrawal in patients on longterm triple therapy without a history of frequent exacerbations.
In the SUNSET (Study to Understand the Safety and Efficacy of ICS Withdrawal from Triple Therapy in COPD) trial we evaluated the efficacy and safety of the direct cessation of ICS from long-term triple therapy to the second-generation LABA/LAMA combination of indacaterol/ glycopyrronium, in nonfrequently exacerbating patients with COPD. Uniquely, we answer the clinically relevant question of which patients on historic triple therapy who do not experience frequent exacerbations can be maintained on effective dual bronchodilator therapy alone.
Methods Study Design
From November 2015 through July 2017 we performed this 26-week, randomized, double-blind, triple-dummy, parallelgroup multicenter study. After a 4-week run-in period on standard triple therapy (tiotropium 18 mg once daily plus combination of salmeterol/fluticasone propionate 50/500 mg twice daily), patients were randomized (1:1) to indacaterol/glycopyrronium (110/50 mg) once daily or triple therapy (tiotropium plus salmeterol/fluticasone) ( Figure 1 ). The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each center and the trial was registered at clinicaltrials.gov (NCT 02603393). All patients provided written informed consent.
Patients
We enrolled patients 40 years of age or older who had stable COPD, a postbronchodilator FEV 1 of at least 40% to less than 80% predicted, a post-bronchodilator ratio of FEV 1 to FVC of less than 0.70, and a smoking history of at least 10 pack-years. Patients were not frequent exacerbators (i.e., they had a history of no more than one moderate or severe exacerbation in the previous year). Patients must have received long-term triple therapy (for at least 6 mo) before enrollment into the study. Patients with a history of asthma and those with a blood eosinophil count greater than 600 cells/ml during screening were excluded from the study. Additional details are provided in the APPENDIX in the online supplement.
Procedures
Patients received either 1) indacaterol/ glycopyrronium 110/50 mg once daily via Breezhaler (Novartis Pharma AG) plus tiotropium-matching placebo once daily via HandiHaler (Boehringer Ingelheim) plus salmeterol/fluticasone-matching placebo via Accuhaler (GlaxoSmithKline); or 2) indacaterol/glycopyrroniummatching placebo once daily via Breezhaler plus tiotropium 18 mg once daily via HandiHaler plus salmeterol/fluticasone
At a Glance Commentary
Scientific Knowledge on the Subject: Add-on inhaled corticosteroids (ICS) are currently recommended for patients with chronic obstructive pulmonary disease (COPD) with frequent exacerbations that occur despite effective long-acting bronchodilator treatment. Many patients receiving triple therapy (i.e., a long-acting b 2 agonist plus a longacting muscarinic antagonist plus an ICS) are not frequent exacerbators. The WISDOM (Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management) study evaluated the stepwise withdrawal of ICS from triple therapy in patients with COPD with a history of exacerbations, but only a proportion of these patients were on triple therapy before study inclusion. There are no randomized controlled trials investigating ICS withdrawal in patients on long-term triple therapy without frequent exacerbations.
What This Study Adds to the
Field: This is the first study to evaluate the efficacy and safety of the direct de-escalation from long-term triple therapy (tiotropium plus salmeterol/ fluticasone) to the once-daily long-acting b 2 agonist/long-acting muscarinic antagonist combination of indacaterol/ glycopyrronium on lung function and exacerbations in patients with moderateto-severe COPD who do not experience frequent exacerbations. In patients with COPD without frequent exacerbations while receiving long-term triple therapy, the direct change to the dual bronchodilator indacaterol/ glycopyrronium led to a small decrease in lung function, with no difference in COPD exacerbations. In patients with >300 blood eosinophils/ml there was a greater decline in lung function and increased exacerbation risk, and these patients are more likely to benefit from continuing triple therapy. However, for most patients the switch did not have any impact on lung function or exacerbations. The results of SUNSET (Study to Understand the Safety and Efficacy of ICS Withdrawal from Triple Therapy in COPD) provide evidence for the personalized management of patients with COPD.
propionate 50/500 mg twice daily via Accuhaler. Salbutamol was provided for use as needed during the study. The study included a 30-day follow-up period to collect patient safety data, during which the study investigator decided on the treatment of the patients.
Outcomes
The primary objective of this study was to demonstrate noninferiority of indacaterol/glycopyrronium versus tiotropium plus salmeterol/fluticasone on change from baseline in postdose trough FEV 1 
Statistical Analysis
Sample size for noninferiority testing on postdose trough FEV 1 at Day 182 for patients in the indacaterol/glycopyrronium group compared with the tiotropium plus salmeterol/fluticasone group assumed a noninferiority margin of 250 ml (13) (14) (15) , an SD of 200 ml, and a one-sided a level of 0.025. To ensure that the study was sufficiently powered (92%), 375 evaluable patients in each treatment arm were required, and taking into account an expected dropout rate of at least 15%, we estimated that approximately 1,000 patients should be enrolled. The primary endpoint was evaluated in the full analysis set (FAS) and confirmed in the per protocol set (PPS) populations. The FAS consisted of all patients in the randomized set who received at least one dose of study medication. Following the intentto-treat principle, patients in the FAS were analyzed according to the treatment to which they were assigned at randomization. The PPS included all patients in the FAS without any major protocol deviations.
The primary analysis of the change from baseline in postdose trough FEV 1 used a mixed-effect model for repeated measures. The model included fixed, categorical effects of treatment and visit, region, and treatment-by-visit interaction as well as continuous, fixed covariates of baseline and baseline-by-visit interaction. Subgroup analyses of the primary endpoint were performed to investigate the relationship between treatment and disease-relevant baseline characteristics (i.e., blood eosinophils, smoking status, FEV 1 reversibility, and exacerbation history). The same mixed-effect model for repeated measures model as the primary endpoint was performed with the inclusion of a treatment by subgroup interaction effect. The mixed model repeated measures is based on the assumption of missing at random and the assumption that dropouts behave similarly to other patients in the same treatment group and similar covariate values, had they not dropped out.
The rate of moderate or severe COPD exacerbations during the treatment period was analyzed using a generalized linear model assuming a negative binomial distribution. The time at risk for a patient was the length of time exposed to study treatment and the model included terms for treatment, region, and COPD 
Results

Patients
A total of 1,684 patients were screened, 1,053 were randomized to the two treatment groups (FAS: 527 in the indacaterol/ glycopyrronium and 526 in the tiotropium plus salmeterol/fluticasone group), and 928 patients completed the study (456 in the indacaterol/glycopyrronium and 472 in the tiotropium plus salmeterol/fluticasone group) ( Figure 2 ). Most of the patients discontinued during screening and run-in were screen failures, with the most common reason being related to spirometric inclusion and exclusion criteria. The PPS included 928 patients (462 in the indacaterol/glycopyrronium and 466 in the tiotropium plus salmeterol/fluticasone group). Baseline demographic and clinical characteristics of the patients are presented in Table 1 ; a total of 70.6% of the randomized patients were male, with a mean post-bronchodilator FEV 1 of 1.6 L (56.6% predicted) and 34.1% had one exacerbation in the previous year. There were no differences in the distribution of patients according to their exacerbation history and the baseline blood eosinophil counts (see Table E5 in the online supplement). Compliance was high in both treatment groups, with 98.7% of the patients in the indacaterol/glycopyrronium and 97.9% in the triple therapy groups achieving >80% compliant days during the double-blind treatment period.
Primary Endpoint
We could not confirm noninferiority of indacaterol/glycopyrronium to tiotropium plus salmeterol/fluticasone in terms of postdose trough FEV 1 Figure 2 . Screening, run-in, randomization, and study completion. *Eight patients who were screen failures in the screening phase returned for the run-in period in error and were once again discontinued.
† These patients were also screening failures (reports were received after initiation of the run-in period). the noninferiority margin (250 ml). In the PPS population, the withdrawal of ICS led to a mean difference of 229 ml (95% CI, 258 to 0 ml) in trough FEV 1 at Week 26 ( Figure 3A) . Over the 26-week treatment period, the withdrawal of ICS resulted in differences in trough FEV 1 between the two treatments of 226 ml to 233 ml ( Figure 3B ). The difference was evident from Day 29 and did not change throughout the 26-week treatment period.
Subgroup analysis of trough FEV 1 by baseline blood eosinophils. There was no significant difference between treatments in postdose trough FEV 1 at Week 26 in patients with baseline blood eosinophil levels of ,2% and eosinophil count of ,300 cells/ml; differences in postdose trough FEV 1 between treatments were higher in patients with high blood eosinophil counts at baseline (>2% or >300 cells/ml) ( Figure 3C ).
Secondary Endpoints
COPD exacerbations. Patients in the two groups experienced similar annualized rates of moderate or severe COPD exacerbations (indacaterol/glycopyrronium vs. tiotropium plus salmeterol/ fluticasone, 0.52 vs. 0.48; rate ratio, 1.08; 95% CI, 0.83 to 1.40) ( Figure 4A ) and all (mild, moderate, and severe) exacerbations (4.11 vs. 3.86; rate ratio, 1.07; 95% CI, 0.93 to 1.22) . There was no difference between treatments in the time to first moderate or severe COPD exacerbation (hazard ratio, 1.11; 95% CI, 0.85 to 1.46) ( Figure 4B ).
SUBGROUP ANALYSIS OF MODERATE OR SEVERE EXACERBATIONS BY BASELINE BLOOD
EOSINOPHILS. The rate of moderate or severe exacerbations according to baseline blood eosinophils subgroups did not differ between the two treatment arms, with the exception of patients with baseline blood eosinophil counts >300 cells/ml who were at increased risk of exacerbations (rate ratio, 1.86; 95% CI, 1.06 to 3.29) ( Figure 4C ). There was no difference in the time to first exacerbation between the two arms in patients with ,300 cells/ml (hazard ratio, 0.95; 95% CI, 0.70 to 1.29) (Figure 4D ), whereas a difference in favor of tiotropium plus salmeterol/fluticasone was observed in patients with >300 cells/ml (hazard ratio, 1.80; 95% CI, 0.98 to 3.28) ( Figure 4E ). In a post hoc analysis, we observed that the patients at increased risk of exacerbations were only those who demonstrated blood eosinophils consistently >300 cells/ml at both the screening and baseline measurements (see Figures E1 and E2) .
Other secondary endpoints. In subgroup analyses of postdose trough FEV 1 , according to baseline characteristics ORIGINAL ARTICLE other than eosinophils, there were no differences between treatments, except for patients who were ex-smokers and those with moderate airflow limitation whose FEV 1 changes favored triple therapy (see Figure E3 ). There were no differences in trough FVC between indacaterol/glycopyrronium and tiotropium plus salmeterol/fluticasone at all the time points of the study (26 ml on Day 29, 25 ml on Day 85, 0 ml on Day 181, and 118 ml on Day 182) (see Figure E4) .
The change from baseline in SGRQ-C score at Week 12 was 20.7 and 22. 
Safety
The incidence of adverse events and serious adverse events were similar across both treatment arms (Table 2) . Adverse events leading to permanent discontinuation of study drug were similar (indacaterol/ glycopyrronium 3.6% and tiotropium plus salmeterol/fluticasone 3.4%). There were numerical differences in ICS-related adverse events (oropharyngeal candidiasis and pneumonias) between the two treatment groups. Seven deaths were reported during the 26-week treatment period (three in indacaterol/glycopyrronium and four in tiotropium plus salmeterol/ fluticasone group).
Discussion
This is the first study to evaluate the direct de-escalation of ICS from long-term triple therapy to the second-generation LABA/LAMA combination of indacaterol/glycopyrronium in a population of low-risk patients with COPD with no more than one exacerbation in the previous year. We have shown that the treatment de-escalation led to a small but significant decrease in lung function of 26 ml in trough FEV 1 with no difference in the rates or risk of COPD exacerbations between treatments. Patients with high blood eosinophils (>300 cells/ml) at baseline showed greater differences in lung function and were at increased risk of exacerbations after ICS withdrawal. Our study answers the clinically relevant question of how to manage patients who are on triple therapy started under previous recommendations (e.g., FEV 1 ,50% predicted and/or >2 exacerbations in the previous year according to Global Initiative for Chronic Obstructive Lung Disease 2011) (6) or those who have been inappropriately escalated.
Although the study did not meet the primary endpoint of noninferiority in trough FEV 1 , the observed reduction of 26 ml in the indacaterol/glycopyrronium versus triple therapy group is consistent with the long-acknowledged small benefit in lung function seen with the use of ICS (16) . This change is of uncertain clinical significance and is too small to be measured reliably in individual patients. Our results show a marginal difference between the two treatments, because the 95% CI (253 to 1 ml) includes the noninferiority margin (250 ml) and does not exclude the margin of 0 ml (17) . This difference was evident 4 weeks after ICS withdrawal and did not change further throughout the treatment period, a finding consistent with the results of the WISDOM study (11) . Importantly, in the current study we were also able to identify that the patients at higher risk for more prominent loss of lung function were those with higher blood eosinophils (i.e., the ones with >300 cells/ml presented a mean decrease of 269 ml).
Older studies that explored the abrupt withdrawal of ICS in patients with COPD showed increase in exacerbations and decline in lung function (18) (19) (20) (21) ; however, these studies used short-acting bronchodilators or twice-daily LABA as maintenance treatment. More recent studies showed that ICS discontinuation from LABA/ICS is safe in the presence of effective long-acting bronchodilation in appropriate patients (22, 23) . The differences in lung function after the abrupt withdrawal of ICS observed in our study are smaller than those observed after the stepwise withdrawal in the WISDOM study (11) . In the SUNSET study we chose the simplified approach of abrupt ICS withdrawal as is often used in clinical practice. This approach is bolstered by the observation from WISDOM that the FEV 1 decrease in the ICS withdrawal group occurred only after the complete withdrawal of ICS (11, 24) . The difference in trough FEV 1 may reflect differences in study populations and potentially the greater efficacy of the dual bronchodilator regimen of the present study (indacaterol/ glycopyrronium vs. salmeterol 1 tiotropium), incorporating a secondgeneration once-daily LABA of greater potency (25) . An interesting observation in the subgroup analyses is the difference in lung function favoring triple therapy in ex-smokers (see Figure E3 ) that may be related to corticosteroid resistance associated with current smoking (26) . However, such subgroup analyses are exploratory and need to be evaluated in specifically designed studies, because the smaller group sizes do not allow for definite conclusions.
In our study, the ICS withdrawal did not have an impact on moderate or severe exacerbations, with the exception of patients with high blood eosinophil counts (>300 cells/ml), confirming a post hoc observation in the WISDOM study (27) . Importantly, all patients included in SUNSET were on prior longterm triple therapy, in contrast to only 39% of patients in WISDOM (11) . High blood eosinophil levels may predict the beneficial effects of ICS on exacerbation reduction on top of a LABA (28, 29) . Dual bronchodilation with indacaterol/ glycopyrronium was superior to LABA/ICS on exacerbation prevention (30) , and the two treatments had similar efficacy in patients with high blood eosinophils in secondary analyses of the FLAME study (31) . Triple therapy is beneficial for exacerbation prevention compared with LAMA (32) or LABA/ICS (33, 34) . Recently, the TRIBUTE study showed that the fixed triple combination of beclomethasone/formoterol/ glycopyrronium only reduced the rate of moderate-to-severe COPD exacerbations but no other exacerbation endpoints in exacerbating patients with COPD (35) . However, it still remains unclear which patients will benefit from ICS on top of LABA/LAMA.
Our study adds evidence for the clinically relevant question as to which patients with COPD can have ICS safely withdrawn from long-term triple therapy, suggesting that these are the nonfrequently exacerbating patients with blood eosinophil counts ,300 cells/ml. These patients were at low risk of future exacerbations during the 6-month follow-up and presented minimal, if any, loss in lung function. The patients with >300 cells/ml in our study may have been frequent exacerbators or had high blood eosinophil counts in the past and, therefore, were appropriately controlled by triple therapy.
Although patients remember accurately the number of exacerbations they experienced in the previous year (36) , no data were available in this study regarding the exacerbation history before the onset of triple therapy. An interesting observation is that in this group, most patients exacerbated in the first weeks after ICS withdrawal ( Figure 4E ), suggesting that patients need to be followed closely during this period. An additional important observation, given the variability of blood eosinophils over time (37) , was that the patients at increased risk for exacerbations were those with consistently >300 cells/ml on two separate occasions (screening and baseline), while all patients were on triple therapy. These data suggest that any therapeutic decisions based on blood eosinophilia might best be based on multiple measurements over time. Such a treatment strategy, however, requires prospective validation.
We observed small differences in total SGRQ-C score in favor of triple therapy that were comparable with those observed in the WISDOM study on ICS withdrawal (11) . The clinical importance of these differences is unknown, because they did not reach the minimal clinically important difference of 24 units and were not associated overall with increased exacerbation risk. The comparable changes from baseline in TDI score and use of rescue medication between the two arms further support the similar symptomatic response between dual bronchodilation and triple therapy.
The recent evidence of increased efficacy of dual bronchodilators compared with LAMA monotherapy and LABA/ICS combinations (30, 38) , combined with the increased risk of potentially serious adverse effects of long-term ICS therapy (39) , suggest that there is a need for precision medicine in COPD (40) , where ICS use is limited to patients in whom the expected treatment effects outweigh risks. Strategies have been proposed for ICS withdrawal in appropriate patients (41) . However, evidence from appropriately designed prospective trials in patients who are stable on long-term triple therapy is missing. In the SUNSET study, we showed that ICS can be effectively and safely withdrawn by switching to the once-daily LABA/LAMA combination of indacaterol/glycopyrronium in not frequently exacerbating patients with COPD with low blood eosinophil counts.
The study has some strengths and limitations. An important strength is that we have studied for the first time the withdrawal of ICS from patients who were stable and nonfrequently exacerbating on long-term triple therapy, providing information that is relevant to clinical practice. An additional strength is the fact that we have carefully excluded patients with a history of asthma, to avoid ICS withdrawal in patients who would benefit from this treatment. The 6-month duration may not be ideal for the evaluation of treatment effects on exacerbations because of seasonal variations. However, there were similar numbers of exacerbations in the two groups in winter-fall and summerspring, with lower numbers of exacerbation events during summerspring, as expected (data not shown). Moreover, patients were recruited across seasons and exacerbations were meticulously collected as per previous methodology (30) , ensuring appropriate reporting of events.
Importantly, the increased risk for exacerbations with >300 eosinophils/ml was observed in the first weeks after ICS withdrawal, providing guidance for the close follow-up of such patients during this period for symptoms deterioration. This duration also may not allow the identification of differences in adverse events related to long-term ICS use between treatment arms; the numerical differences in oral candidiasis and pneumonia, however, may be suggestive of an increased risk of ICS-related adverse events in the triple therapy arm. Importantly, all patients included in the study had previously been on long-term ICS regimens and most likely had not experienced serious ICS-related side effects. Finally, we evaluated ICS withdrawal from triple therapy to a specific second-generation LABA/LAMA combination (indacaterol/glycopyrronium); it is likely that the results are influenced also by the different bronchodilators and, therefore, may not be applicable to other drug combinations. Therefore, this study cannot be considered as a "pure" ICS withdrawal study, because the LABA and LAMA components differ; however, our results address the clinically relevant question whether the switch from prescribed triple therapy to a modern LABA/LAMA fixed-dose combination is appropriate.
In conclusion, in patients on long-term triple therapy and no more than one exacerbation in the previous year, the direct change to indacaterol/glycopyrronium led to a small decrease in lung function, but with no significant difference in the rates of COPD exacerbations between treatments. For most patients, the switch to indacaterol/ glycopyrronium did not have any impact on lung function or exacerbations, while avoiding the long-term exposure to ICS and related adverse effects. A difference in exacerbations in patients with consistently high blood eosinophils (>300 cells/ml), measured while on triple therapy, suggests that it is these patients who will most likely benefit from continuation of triple therapy. These results are clinically relevant and may support the personalized management of patients with COPD. n Author disclosures are available with the text of this article at www.atsjournals.org.
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